Evaluating Y-mAbs Therapy: Insights from 5 Financial Analysts – Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapy YMAB Over the past three months, 5 analysts have analyzed it, revealing a wide range of prospects, from bullish to bearish.

The table below summarizes their latest ratings, showing how sentiment has changed over the past 30 days and comparing it to previous months.

	Bullish	Rather bullish	Inert	A bit bear-like	Bearish
Total number of ratings	3	1	0	1	0
Last 30D	1	1	0	1	0
1M ago	0	0	0	0	0
2M ago	2	0	0	0	0
3M ago	0	0	0	0	0

Providing a deeper insight, the analysts have set 12-month price targets, indicating an average target of $20.40, along with a high of $25.00 and a low of $11.00. Seeing a 2.0% upside, the current average is up from the previous average price target of $20.00.

Diving into Analyst Ratings: An In-Depth Exploration

The perception of Y-mAbs Therapeutics by financial experts is analyzed through recent analyst activity. The summary below presents key analysts, their latest ratings, and revisions to ratings and price targets.

Analyst	Analytical firm	Action taken	Rate	Current target price	Previous Price Target
Michael Ulz	Morgan Stanley	It lowers	Underweight	11.00 PLN	12.00 PLN
Robert Burns	H. C. Wainwright & Co.	It maintains	To buy	22.00 PLN	22.00 PLN
Etzer Darout	BMO Capital	It lowers	To surpass	25.00 PLN	26.00 PLN
Justin Walsh	Trade Jones	He announces	To buy	23.00 PLN	–
Nicole Germino	Truist Securities	He announces	To buy	21.00 PLN	–

Key information:

• Actions taken: Analysts react to changes in market conditions and company results by frequently updating their recommendations. Whether they “hold,” “raise,” or “lower” their stance, it reflects their reaction to the latest developments surrounding Y-mAbs Therapeutics. This information provides a picture of how analysts view the current state of the company.
• Rate: Analyzing the trends, analysts offer qualitative ratings ranging from “Outperform” to “Underperform.” These ratings convey expectations about Y-mAbs Therapeutics’ relative performance compared to the broader market.
• Pricing goals: Gaining insight, analysts provide estimates of the future value of Y-mAbs Therapeutics stock. This comparison reveals trends in analyst expectations over time.

Navigating these analyst ratings along with other financial metrics can help you gain a holistic understanding of Y-mAbs Therapeutics’ market position. Stay informed and make data-driven decisions with our Ratings Dashboard.

Stay up to date with analyst ratings for Y-mAbs Therapeutics.

If you’re interested in small-cap stock news and performance, you can start by following them here.

We delve into the history of Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc. is a commercial-stage biopharmaceutical company primarily engaged in the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer. DANYELZA is the company’s first FDA-approved product, which is a recombinant humanized immunoglobulin G, subtype 1k or IgG1k monoclonal antibody or mAb that targets the ganglioside GD2, which is expressed in various neuroectodermal tumors and sarcomas.

Uncovering the Financial History of Y-mAbs Therapeutics

Market Capitalization Analysis: The company’s market capitalization is above the industry average, indicating the company’s dominant size compared to its competitors and strong market position.

Decrease in revenue: During the 3-month period, Y-mAbs Therapeutics faced challenges that resulted in a decrease of approximately -1.58% revenue growth as of March 31, 2024. This represents a decrease in the company’s profits. Compared to its peers in the healthcare sector, the company faces challenges, achieving a growth rate lower than the average among its competitors.

Net margin: The company’s net margin is outstanding, exceeding industry averages. With an impressive net margin of -33.26%, the company is characterized by high profitability and effective cost control.

Return on Equity (ROE): The financial strength of Y-mAbs Therapeutics is reflected in its exceptional ROE, which exceeds the industry average. With an extraordinary ROE of -6.62%, the company is characterized by effective use of equity capital and good financial condition.

Return on assets (ROA): Y-mAbs Therapeutics ROA exceeds industry standards, highlighting the company’s exceptional financial performance. With an impressive -5.28% ROA, the company efficiently uses its assets to obtain optimal profits.

Debt management: Y-mAbs Therapeutics’ debt to equity ratio is lower than the industry average and stands at 0.01reflecting less reliance on debt financing and a more conservative financial approach.

What are analyst ratings?

Analyst ratings are the go-to indicators of stock performance, provided by experts in banking and financial systems. These specialists meticulously analyze company financial statements, participate in conference calls, and work with insiders to generate quarterly ratings for individual stocks.

Some analysts also offer forecasts on metrics such as growth estimates, earnings, and revenues to provide further guidance on the stock. Investors using analyst ratings should remember that this expert advice comes from humans and may be subject to error.

This article was generated by Benzinga’s automated content creation engine and reviewed by an editor.